Cytokinetics EVP, Chief Commercial Officer Andrew Callos sells 14,000 common shares for $1.12 million

Reuters2026/07/30 20:27

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cytokinetics EVP and Chief Commercial Officer Andrew Callos sold 14,000 common shares on July 30, 2026 at USD 79.88.
He exercised 14,000 non-qualified stock options at USD 23.26 in the same filing.
Directly held common shares fell to 58,555 following the transactions.
Callos reported 10,000 options remaining after the exercise.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001061983-26-000086), on July 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cytokinetics EVP, Chief Commercial Officer Andrew Callos sells 14,000 common shares for $1.12 million

You may also like

Crypto prices